KatarinaLuptakovaMD
Hematology • Boston, MAHematologic Oncology
Instructor in Medicine, Beth Israel Deaconess Medical Center
Dr. Luptakova is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Beth Israel Deaconess Medical Center
330 Brookline Ave.
Boston, MA 02215- Is this information wrong?
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
St Elizabeth's Medical CenterResidency, Internal Medicine, 2003 - 2006
Comenius UniversityClass of 2000
Certifications & Licensure
MA State Medical License 2006 - 2023
Clinical Trials
- Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Start of enrollment: 2011 Sep 01
- Lenalidomide After Allo Transplant Start of enrollment: 2012 Dec 01
- Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma Start of enrollment: 2015 Dec 01
Publications & Presentations
PubMed
- 7 citationsc-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.Alessandra Di Bacco, Nizar J. Bahlis, Nikhil C. Munshi, Hervé Avet-Loiseau, Tamás Masszi, Luisa Viterbo, Ludek Pour, Peter Ganly, Michele Cavo, Christian Langer, Shaji...> ;European Journal of Haematology. 2020 Mar 7
- 289 citationsNiraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N. Moore, Angeles Alvarez Secord, Melissa A. Geller, David Miller, N.G. Cloven, Gini F. Fleming, Andrea E. Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro,...> ;The Lancet. Oncology. 2019 May 1
- 8 citationsReal-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in FranceHuamao Mark Lin, Keith L. Davis, James A. Kaye, Katarina Luptakova, Saurabh P Nagar, Mohamad Mohty> ;Advances in Hematology. 2019 Jan 29
- Join now to see all
Press Mentions
The Courage of Patients in Phase 1 Cancer TrialsMay 31st, 2022
Hospital Affiliations
Beth Israel Deaconess Medical CenterBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
